{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:39:14Z","timestamp":1787002754805,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"42","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Androgen receptor (AR)-mediated signaling is essential for PC tumorigenesis. In the TCGA database we observed a positive correlation between ECD and AR expression. Consistently, Dihydrotestosterone (DHT) treatment of PC cell lines increased ECD mRNA and protein levels, and AR knockdown (KD) reduced ECD expression. Bioinformatic analysis predicted three consensus androgen response elements in the ECD promoter, and DHT treatment increased AR occupancy at the ECD promoter, and enhanced ECD promoter activity. Enzalutamide treatment decreased ECD levels, and ECD knockout (KO) in PC cells reduced oncogenic traits, suggesting a functional role of ECD to maintain PC oncogenesis. ECD mRNA and protein are overexpressed in PC patient tissues, and its overexpression predicts shorter survival. Overexpression of ECD in PC cell lines enhanced the oncogenic traits in vitro and developed faster and larger highly proliferative xenograft tumors. RNA-seq analysis of mouse tumors revealed an increase in mRNA levels of several glycolytic genes. ECD associates with mRNA of key glycolytic genes and is required for their stability, consistent with our recent demonstration of ECD is an RNA binding protein. Higher glucose uptake and glycolysis was seen upon ECD overexpression in PC cells. Together, we demonstrate the role of a novel AR target gene ECD in PC tumorigenesis.<\/jats:p>","DOI":"10.1038\/s41388-025-03559-x","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T18:32:41Z","timestamp":1757010761000},"page":"4058-4074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis"],"prefix":"10.1038","volume":"44","author":[{"given":"Mohsin","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7763-7160","authenticated-orcid":false,"given":"Asher Rajkumar","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin B.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Reznicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshid","family":"Oruji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Jordan","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4149-5487","authenticated-orcid":false,"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaustubh","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3434-4306","authenticated-orcid":false,"given":"Bhopal C.","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4996-9002","authenticated-orcid":false,"given":"Hamid","family":"Band","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimla","family":"Band","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"3559_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"3559_CR2","first-page":"232","volume":"22","author":"C Huggins","year":"1972","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232\u201340.","journal-title":"CA Cancer J Clin"},{"key":"3559_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/PPO.0b013e318282635a","volume":"19","author":"D Rathkopf","year":"2013","unstructured":"Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J. 2013;19:43\u201349.","journal-title":"Cancer J"},{"key":"3559_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"3559_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41585-021-00470-4","volume":"18","author":"SD Lokeshwar","year":"2021","unstructured":"Lokeshwar SD, Klaassen Z, Saad F. Treatment and trials in non-metastatic castration-resistant prostate cancer. Nat Rev Urol. 2021;18:433\u201342.","journal-title":"Nat Rev Urol"},{"key":"3559_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","volume":"125","author":"F Ahmad","year":"2021","unstructured":"Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. Br J Cancer. 2021;125:1185\u201396.","journal-title":"Br J Cancer"},{"key":"3559_CR7","doi-asserted-by":"crossref","unstructured":"Lasorsa F, di Meo NA, Rutigliano M, Ferro M, Terracciano D, Tataru OS, et al. Emerging hallmarks of metabolic reprogramming in prostate cancer. Int J Mol Sci. 2023;24:910.","DOI":"10.3390\/ijms24020910"},{"key":"3559_CR8","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41388-021-02157-x","volume":"41","author":"L de Wet","year":"2022","unstructured":"de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, et al. SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. 2022;41:1190\u2013202.","journal-title":"Oncogene"},{"key":"3559_CR9","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1172\/JCI99397","volume":"128","author":"R Mishra","year":"2018","unstructured":"Mishra R, Haldar S, Placencio V, Madhav A, Rohena-Rivera K, Agarwal P, et al. Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. J Clin Invest. 2018;128:4472\u201384.","journal-title":"J Clin Invest"},{"key":"3559_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/path.2809","volume":"223","author":"R Flavin","year":"2011","unstructured":"Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol. 2011;223:283\u201394.","journal-title":"J Pathol"},{"key":"3559_CR11","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00432-022-04371-w","volume":"149","author":"AK Beier","year":"2023","unstructured":"Beier AK, Puhr M, Stope MB, Thomas C, Erb HHH. Metabolic changes during prostate cancer development and progression. J Cancer Res Clin Oncol. 2023;149:2259\u201370.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3559_CR12","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1242\/dev.01143","volume":"131","author":"I Gaziova","year":"2004","unstructured":"Gaziova I, Bonnette PC, Henrich VC, Jindra M. Cell-autonomous roles of the ecdysoneless gene in Drosophila development and oogenesis. Development. 2004;131:2715\u201325.","journal-title":"Development"},{"key":"3559_CR13","doi-asserted-by":"publisher","first-page":"26402","DOI":"10.1074\/jbc.M109.030551","volume":"284","author":"JH Kim","year":"2009","unstructured":"Kim JH, Gurumurthy CB, Naramura M, Zhang Y, Dudley AT, Doglio L, et al. Role of mammalian Ecdysoneless in cell cycle regulation. J Biol Chem. 2009;284:26402\u201310.","journal-title":"J Biol Chem"},{"key":"3559_CR14","doi-asserted-by":"crossref","unstructured":"Olou AA, Sarkar A, Bele A, Gurumurthy CB, Mir RA, Ammons SA, et al. Mammalian ECD protein is a novel negative regulator of the PERK arm of the unfolded protein response. Mol Cell Biol. 2017;37.","DOI":"10.1128\/MCB.00030-17"},{"key":"3559_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1515\/bc.2010.004","volume":"391","author":"JH Kim","year":"2010","unstructured":"Kim JH, Gurumurthy CB, Band H, Band V. Biochemical characterization of human Ecdysoneless reveals a role in transcriptional regulation. Biol Chem. 2010;391:9\u201319.","journal-title":"Biol Chem"},{"key":"3559_CR16","doi-asserted-by":"publisher","first-page":"e1004287","DOI":"10.1371\/journal.pgen.1004287","volume":"10","author":"AK Claudius","year":"2014","unstructured":"Claudius AK, Romani P, Lamkemeyer T, Jindra M, Uhlirova M. Unexpected role of the steroid-deficiency protein ecdysoneless in pre-mRNA splicing. PLoS Genet. 2014;10:e1004287.","journal-title":"PLoS Genet"},{"key":"3559_CR17","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1083\/jcb.201701165","volume":"216","author":"A Malinova","year":"2017","unstructured":"Malinova A, Cvackova Z, Mateju D, Horejsi Z, Abeza C, Vandermoere F, et al. Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90\/R2TP chaperones. J Cell Biol. 2017;216:1579\u201396.","journal-title":"J Cell Biol"},{"key":"3559_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00103-21","volume":"41","author":"I Saleem","year":"2021","unstructured":"Saleem I, Mirza S, Sarkar A, Raza M, Mohapatra B, Mushtaq I, et al. The Mammalian Ecdysoneless Protein Interacts with RNA Helicase DDX39A To Regulate Nuclear mRNA Export. Mol Cell Biol. 2021;41:e0010321.","journal-title":"Mol Cell Biol"},{"key":"3559_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1541-7786.MCR-21-0567","volume":"20","author":"S Mirza","year":"2022","unstructured":"Mirza S, Kalluchi A, Raza M, Saleem I, Mohapatra B, Pal D, et al. Ecdysoneless protein regulates viral and cellular mRNA splicing to promote cervical oncogenesis. Mol Cancer Res. 2022;20:305\u201318.","journal-title":"Mol Cancer Res"},{"key":"3559_CR20","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1158\/1078-0432.CCR-12-1789","volume":"18","author":"P Dey","year":"2012","unstructured":"Dey P, Rachagani S, Chakraborty S, Singh PK, Zhao X, Gurumurthy CB, et al. Overexpression of ecdysoneless in pancreatic cancer and its role in oncogenesis by regulating glycolysis. Clin Cancer Res. 2012;18:6188\u201398.","journal-title":"Clin Cancer Res"},{"key":"3559_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/path.4515","volume":"236","author":"SH Xu","year":"2015","unstructured":"Xu SH, Huang JZ, Xu ML, Yu G, Yin XF, Chen D, et al. ACK1 promotes gastric cancer epithelial-mesenchymal transition and metastasis through AKT-POU2F1-ECD signalling. J Pathol. 2015;236:175\u201385.","journal-title":"J Pathol"},{"key":"3559_CR22","doi-asserted-by":"publisher","first-page":"12705","DOI":"10.18632\/oncotarget.6194","volume":"8","author":"SH Xu","year":"2017","unstructured":"Xu SH, Huang JZ, Chen M, Zeng M, Zou FY, Chen D, et al. Amplification of ACK1 promotes gastric tumorigenesis via ECD-dependent p53 ubiquitination degradation. Oncotarget. 2017;8:12705\u201316.","journal-title":"Oncotarget"},{"key":"3559_CR23","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1158\/1541-7786.MCR-22-0122","volume":"20","author":"BC Mohapatra","year":"2022","unstructured":"Mohapatra BC, Mirza S, Bele A, Gurumurthy CB, Raza M, Saleem I, et al. Ecdysoneless overexpression drives mammary tumorigenesis through upregulation of C-MYC and glucose metabolism. Mol Cancer Res. 2022;20:1391\u2013404.","journal-title":"Mol Cancer Res"},{"key":"3559_CR24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s42003-023-05125-1","volume":"6","author":"S Chakraborty","year":"2023","unstructured":"Chakraborty S, Bhat AM, Mushtaq I, Luan H, Kalluchi A, Mirza S, et al. EHD1-dependent traffic of IGF-1 receptor to the cell surface is essential for Ewing sarcoma tumorigenesis and metastasis. Commun Biol. 2023;6:758.","journal-title":"Commun Biol"},{"key":"3559_CR25","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1080\/15384101.2015.1006982","volume":"14","author":"A Bele","year":"2015","unstructured":"Bele A, Mirza S, Zhang Y, Ahmad Mir R, Lin S, Kim JH, et al. The cell cycle regulator ecdysoneless cooperates with H-Ras to promote oncogenic transformation of human mammary epithelial cells. Cell Cycle. 2015;14:990\u20131000.","journal-title":"Cell Cycle"},{"key":"3559_CR26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38:276\u20138.","journal-title":"Nat Biotechnol"},{"key":"3559_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nbt.3820","volume":"35","author":"P Di Tommaso","year":"2017","unstructured":"Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, Notredame C. Nextflow enables reproducible computational workflows. Nat Biotechnol. 2017;35:316\u20139.","journal-title":"Nat Biotechnol"},{"key":"3559_CR28","doi-asserted-by":"publisher","first-page":"e0177459","DOI":"10.1371\/journal.pone.0177459","volume":"12","author":"GM Kurtzer","year":"2017","unstructured":"Kurtzer GM, Sochat V, Bauer MW. Singularity: scientific containers for mobility of compute. PLoS One. 2017;12:e0177459.","journal-title":"PLoS One"},{"key":"3559_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"3559_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1910-1","volume":"20","author":"S Kovaka","year":"2019","unstructured":"Kovaka S, Zimin AV, Pertea GM, Razaghi R, Salzberg SL, Pertea M. Transcriptome assembly from long-read RNA-seq alignments with StringTie2. Genome Biol. 2019;20:278.","journal-title":"Genome Biol"},{"key":"3559_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"3559_CR32","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3559_CR33","first-page":"5010","volume":"42","author":"JT Isaacs","year":"1982","unstructured":"Isaacs JT. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas. Cancer Res. 1982;42:5010\u20134.","journal-title":"Cancer Res"},{"key":"3559_CR34","doi-asserted-by":"publisher","first-page":"T179","DOI":"10.1530\/ERC-16-0422","volume":"23","author":"I Coutinho","year":"2016","unstructured":"Coutinho I, Day TK, Tilley WD, Selth LA. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer. 2016;23:T179\u2013T197.","journal-title":"Endocr Relat Cancer"},{"key":"3559_CR35","first-page":"2577","volume":"54","author":"GN Thalmann","year":"1994","unstructured":"Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54:2577\u201381.","journal-title":"Cancer Res"},{"key":"3559_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mce.2004.04.013","volume":"222","author":"BJ Attardi","year":"2004","unstructured":"Attardi BJ, Burgenson J, Hild SA, Reel JR. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. Mol Cell Endocrinol. 2004;222:121\u201332.","journal-title":"Mol Cell Endocrinol"},{"key":"3559_CR37","first-page":"163","volume":"15","author":"S Korenchuk","year":"2001","unstructured":"Korenchuk S, Lehr JE, MC L, Lee YG, Whitney S, Vessella R, et al. VCaP, a cell-based model system of human prostate cancer. Vivo. 2001;15:163\u20138.","journal-title":"Vivo"},{"key":"3559_CR38","first-page":"1809","volume":"43","author":"JS Horoszewicz","year":"1983","unstructured":"Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983;43:1809\u201318.","journal-title":"Cancer Res"},{"key":"3559_CR39","doi-asserted-by":"publisher","first-page":"10765","DOI":"10.1093\/nar\/gks888","volume":"40","author":"KF Decker","year":"2012","unstructured":"Decker KF, Zheng D, He Y, Bowman T, Edwards JR, Jia L. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res. 2012;40:10765\u201379.","journal-title":"Nucleic Acids Res"},{"key":"3559_CR40","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/cr.2009.43","volume":"19","author":"I Bisson","year":"2009","unstructured":"Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009;19:683\u201397.","journal-title":"Cell Res"},{"key":"3559_CR41","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/j.1939-4640.2003.tb02727.x","volume":"24","author":"YS Zhu","year":"2003","unstructured":"Zhu YS, Cai LQ, You X, Cordero JJ, Huang Y, Imperato-McGinley J. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. J Androl. 2003;24:681\u20137.","journal-title":"J Androl"},{"key":"3559_CR42","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.molcel.2007.05.041","volume":"27","author":"Q Wang","year":"2007","unstructured":"Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell. 2007;27:380\u201392.","journal-title":"Mol Cell"},{"key":"3559_CR43","doi-asserted-by":"publisher","first-page":"W247","DOI":"10.1093\/nar\/gkp464","volume":"37","author":"F Zambelli","year":"2009","unstructured":"Zambelli F, Pesole G, Pavesi G. Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes. Nucleic Acids Res. 2009;37:W247\u2013252.","journal-title":"Nucleic Acids Res"},{"key":"3559_CR44","doi-asserted-by":"publisher","first-page":"D51","DOI":"10.1093\/nar\/gkw1069","volume":"45","author":"R Dreos","year":"2017","unstructured":"Dreos R, Ambrosini G, Groux R, Cavin Perier R, Bucher P. The eukaryotic promoter database in its 30th year: focus on non-vertebrate organisms. Nucleic Acids Res. 2017;45:D51\u2013D55.","journal-title":"Nucleic Acids Res"},{"key":"3559_CR45","doi-asserted-by":"publisher","first-page":"W39","DOI":"10.1093\/nar\/gkv416","volume":"43","author":"TL Bailey","year":"2015","unstructured":"Bailey TL, Johnson J, Grant CE, Noble WS. The MEME Suite. Nucleic Acids Res. 2015;43:W39\u201349.","journal-title":"Nucleic Acids Res"},{"key":"3559_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eururo.2013.08.011","volume":"66","author":"P Rajan","year":"2014","unstructured":"Rajan P, Sudbery IM, Villasevil ME, Mui E, Fleming J, Davis M, et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol. 2014;66:32\u201339.","journal-title":"Eur Urol"},{"key":"3559_CR47","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.21873\/anticanres.15113","volume":"41","author":"HHH Erb","year":"2021","unstructured":"Erb HHH, Oster MA, Gelbrich N, Cammann C, Thomas C, Mustea A, et al. Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System. Anticancer Res. 2021;41:3271\u20139.","journal-title":"Anticancer Res"},{"key":"3559_CR48","doi-asserted-by":"publisher","first-page":"16711","DOI":"10.1002\/jcb.28929","volume":"120","author":"A Abazid","year":"2019","unstructured":"Abazid A, Martin B, Choinowski A, McNeill RV, Brandenburg LO, Ziegler P, et al. The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor beta1 expression in prostate cancer cells. J Cell Biochem. 2019;120:16711\u201322.","journal-title":"J Cell Biochem"},{"key":"3559_CR49","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.18632\/oncotarget.6261","volume":"7","author":"CH Lee","year":"2016","unstructured":"Lee CH, Yu CC, Wang BY, Chang WW. Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs. Oncotarget. 2016;7:1215\u201326.","journal-title":"Oncotarget"},{"key":"3559_CR50","doi-asserted-by":"publisher","first-page":"39676","DOI":"10.18632\/oncotarget.5344","volume":"6","author":"G Bredholt","year":"2015","unstructured":"Bredholt G, Mannelqvist M, Stefansson IM, Birkeland E, Bo TH, Oyan AM, et al. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. Oncotarget. 2015;6:39676\u201391.","journal-title":"Oncotarget"},{"key":"3559_CR51","first-page":"867","volume":"138","author":"J Gerdes","year":"1991","unstructured":"Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138:867\u201373.","journal-title":"Am J Pathol"},{"key":"3559_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112937","volume":"42","author":"N Tabrizian","year":"2023","unstructured":"Tabrizian N, Nouruzi S, Cui CJ, Kobelev M, Namekawa T, Lodhia I, et al. ASCL1 is activated downstream of the ROR2\/CREB signaling pathway to support lineage plasticity in prostate cancer. Cell Rep. 2023;42:112937.","journal-title":"Cell Rep"},{"key":"3559_CR53","doi-asserted-by":"publisher","first-page":"E6544","DOI":"10.1073\/pnas.1518007112","volume":"112","author":"BA Smith","year":"2015","unstructured":"Smith BA, Sokolov A, Uzunangelov V, Baertsch R, Newton Y, Graim K, et al. A basal stem cell signature identifies aggressive prostate cancer phenotypes. Proc Natl Acad Sci USA. 2015;112:E6544\u20136552.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3559_CR54","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.ajpath.2012.08.005","volume":"181","author":"L Agell","year":"2012","unstructured":"Agell L, Hernandez S, Nonell L, Lorenzo M, Puigdecanet E, de Muga S, et al. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression. Am J Pathol. 2012;181:1585\u201394.","journal-title":"Am J Pathol"},{"key":"3559_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111097","volume":"40","author":"R Islam","year":"2022","unstructured":"Islam R, Mishra J, Polavaram NS, Bhattacharya S, Hong Z, Bodas S, et al. Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance. Cell Rep. 2022;40:111097.","journal-title":"Cell Rep"},{"key":"3559_CR56","doi-asserted-by":"crossref","unstructured":"Raza M, Rajan AR, Kalluchi A, Saleem I, Kennedy BB, Bhakat KK, et al. ECD functions as a novel RNA-binding protein to regulate mRNA splicing. bioRxiv 2025: 2025.2001.2024.634785.","DOI":"10.1101\/2025.01.24.634785"},{"key":"3559_CR57","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/nar\/gkaa1274","volume":"49","author":"S Erkelenz","year":"2021","unstructured":"Erkelenz S, Stankovic D, Mundorf J, Bresser T, Claudius AK, Boehm V, et al. Ecd promotes U5 snRNP maturation and Prp8 stability. Nucleic Acids Res. 2021;49:1688\u2013707.","journal-title":"Nucleic Acids Res"},{"key":"3559_CR58","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519\u201330.","journal-title":"J Gen Physiol"},{"key":"3559_CR59","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s42255-021-00367-x","volume":"3","author":"H Xie","year":"2021","unstructured":"Xie H, Song J, Godfrey J, Riscal R, Skuli N, Nissim I, et al. Glycogen metabolism is dispensable for tumour progression in clear cell renal cell carcinoma. Nat Metab. 2021;3:327\u201336.","journal-title":"Nat Metab"},{"key":"3559_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05084-1","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zhou Q, Hankey W, Fang X, Yuan F. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis. 2022;13:632.","journal-title":"Cell Death Dis"},{"key":"3559_CR61","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10549-011-1946-8","volume":"134","author":"X Zhao","year":"2012","unstructured":"Zhao X, Mirza S, Alshareeda A, Zhang Y, Gurumurthy CB, Bele A, et al. Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2\/neu-overexpressing breast cancer patients. Breast Cancer Res Treat. 2012;134:171\u201380.","journal-title":"Breast Cancer Res Treat"},{"key":"3559_CR62","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1093\/nar\/gkab185","volume":"49","author":"M Kulik","year":"2021","unstructured":"Kulik M, Bothe M, Kibar G, Fuchs A, Schone S, Prekovic S, et al. Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites. Nucleic Acids Res. 2021;49:3856\u201375.","journal-title":"Nucleic Acids Res"},{"key":"3559_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1437179","volume":"15","author":"J Hiltunen","year":"2024","unstructured":"Hiltunen J, Helminen L, Paakinaho V. Glucocorticoid receptor action in prostate cancer: the role of transcription factor crosstalk. Front Endocrinol (Lausanne). 2024;15:1437179.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3559_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.11.015","volume":"75","author":"AM Acosta","year":"2018","unstructured":"Acosta AM, Al Rasheed MRH, Rauscher GH, Vormittag E, Mon KS, Sharif A, et al. Tumor necrosis in radical prostatectomies with high-grade prostate cancer is associated with multiple poor prognostic features and a high prevalence of residual disease. Hum Pathol. 2018;75:1\u20139.","journal-title":"Hum Pathol"},{"key":"3559_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10685-w","volume":"23","author":"S Ma","year":"2023","unstructured":"Ma S, Chen Y, Quan P, Zhang J, Han S, Wang G, et al. NPAS2 promotes aerobic glycolysis and tumor growth in prostate cancer through HIF-1A signaling. BMC Cancer. 2023;23:280.","journal-title":"BMC Cancer"},{"key":"3559_CR66","doi-asserted-by":"crossref","unstructured":"Zhou Y, Zeng F, Richards GO, Wang N. ENO2, a glycolytic enzyme, contributes to prostate cancer metastasis: a systematic review of literature. Cancers (Basel). 2024;16:2503.","DOI":"10.3390\/cancers16142503"},{"key":"3559_CR67","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1530\/ERC-14-0107","volume":"21","author":"Y Cui","year":"2014","unstructured":"Cui Y, Nadiminty N, Liu C, Lou W, Schwartz CT, Gao AC. Upregulation of glucose metabolism by NF-kappaB2\/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer. 2014;21:435\u201342.","journal-title":"Endocr Relat Cancer"},{"key":"3559_CR68","doi-asserted-by":"crossref","unstructured":"Gillis JL, Hinneh JA, Ryan NK, Irani S, Moldovan M, Quek LE, et al. A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth. Elife. 2021;10:e62592.","DOI":"10.7554\/eLife.62592"},{"key":"3559_CR69","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1158\/0008-5472.CAN-17-3226","volume":"78","author":"J Liu","year":"2018","unstructured":"Liu J, Chen G, Liu Z, Liu S, Cai Z, You P, et al. Aberrant FGFR tyrosine kinase signaling enhances the Warburg effect by reprogramming LDH isoform expression and activity in prostate cancer. Cancer Res. 2018;78:4459\u201370.","journal-title":"Cancer Res"},{"key":"3559_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-024-00469-y","volume":"19","author":"B Yang","year":"2024","unstructured":"Yang B, Chen W, Tao T, Zhang J, Kong D, Hao J, et al. UBE2N promotes cell viability and glycolysis by promoting Axin1 ubiquitination in prostate cancer cells. Biol Direct. 2024;19:35.","journal-title":"Biol Direct"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03559-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T22:03:28Z","timestamp":1760393008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03559-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":70,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2025,11,4]]}},"alternative-id":["3559"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03559-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.30.635534","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental methods were performed in accordance with the relevant guidelines and regulations. Animal experiments were pre-approved by the UNMC Institutional Animal Care and Use Committee (IACUC Protocol # 22-059-10-FC). The prostate cancer tissue specimens were obtained with informed consent from patients who underwent radical prostatectomy at the Department of Urology, Institute for Pathology, University Hospital \u201cCarl-Gustav-Carus\u201d, University of Technology, Dresden between 1999 and 2005. The Charite approved the use of PC tissue samples by the University Ethics Committee under the protocol \u2018Retrospective analysis of tissue samples by immunohistochemistry and molecular biological techniques\u2019 (EA1\/06\/2004) on 20 September 2004.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}}]}}